HC Wainwright Brokers Lift Earnings Estimates for BrainsWay

BrainsWay Ltd. (NASDAQ:BWAY) – HC Wainwright raised their FY2024 earnings per share (EPS) estimates for shares of BrainsWay in a research note issued on Monday, December 23rd. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of $0.14 per share for the year, up from their previous estimate of $0.06. HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for BrainsWay’s current full-year earnings is $0.06 per share. HC Wainwright also issued estimates for BrainsWay’s Q4 2024 earnings at $0.06 EPS, Q1 2025 earnings at $0.06 EPS, Q2 2025 earnings at $0.08 EPS, Q3 2025 earnings at $0.08 EPS, Q4 2025 earnings at $0.10 EPS and FY2025 earnings at $0.32 EPS.

BrainsWay (NASDAQ:BWAY) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.03. The business had revenue of $10.50 million for the quarter, compared to analyst estimates of $10.07 million. BrainsWay had a net margin of 3.88% and a return on equity of 3.52%. During the same period in the prior year, the business posted ($0.01) earnings per share.

Separately, Northland Securities boosted their target price on BrainsWay from $11.00 to $12.50 and gave the stock an “outperform” rating in a research report on Thursday, October 3rd.

BrainsWay Trading Up 0.2 %

NASDAQ BWAY opened at $9.37 on Wednesday. BrainsWay has a 12 month low of $4.61 and a 12 month high of $10.98. The stock has a 50-day simple moving average of $9.83 and a 200 day simple moving average of $8.27. The company has a market capitalization of $176.28 million, a PE ratio of 93.71 and a beta of 1.23.

Institutional Investors Weigh In On BrainsWay

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. boosted its stake in shares of BrainsWay by 316.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 14,769 shares of the company’s stock worth $136,000 after acquiring an additional 11,221 shares during the period. Rhumbline Advisers increased its holdings in shares of BrainsWay by 10.3% during the second quarter. Rhumbline Advisers now owns 18,077 shares of the company’s stock worth $110,000 after buying an additional 1,695 shares in the last quarter. Perritt Capital Management Inc acquired a new position in BrainsWay in the 2nd quarter worth about $121,000. Good Life Advisors LLC raised its holdings in BrainsWay by 65.5% in the 3rd quarter. Good Life Advisors LLC now owns 55,800 shares of the company’s stock valued at $516,000 after buying an additional 22,080 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its holdings in shares of BrainsWay by 48.1% during the second quarter. Acadian Asset Management LLC now owns 259,787 shares of the company’s stock worth $1,567,000 after purchasing an additional 84,371 shares during the period. 30.11% of the stock is owned by institutional investors.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.